Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,708,544
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.66
  • Price/Sales 7.06
  • Price/Cash Flow 19.08
  • Price/Book 16.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.52 +4.73%
on 04/25/18
50.31 -3.15%
on 05/14/18
+0.04 (+0.08%)
since 04/18/18
3-Month
46.52 +4.73%
on 04/25/18
54.56 -10.70%
on 02/26/18
-3.14 (-6.05%)
since 02/16/18
52-Week
40.78 +19.47%
on 05/19/17
58.37 -16.53%
on 01/23/18
+8.28 (+20.47%)
since 05/18/17

Most Recent Stories

More News
Top Research Reports for Walmart, AT&T & Novo Nordisk

Top Research Reports for Walmart, AT&T & Novo Nordisk

T : 32.05 (+0.38%)
BCE : 42.16 (-0.28%)
NVO : 48.72 (-0.55%)
CI : 178.07 (-0.47%)
AGN : 158.43 (-1.12%)
WMT : 83.64 (-1.01%)
BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

STOCKHOLM, May 16, 2018 /PRNewswire/ --

NVO : 48.72 (-0.55%)
Global Human Growth Hormones Deficiency Drugs Market, 2018-2023 Featuring Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

The "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" report has been added to ResearchAndMarkets.com's...

ASND : 66.29 (-0.94%)
NVO : 48.72 (-0.55%)
OPK : 3.99 (-18.24%)
PFE : 35.64 (-0.20%)
INDYCAR Driver Charlie Kimball and Novo Nordisk unveil new No. 23 Fiasp® Chevrolet® for 2 races in Indianapolis during the month of May

Charlie Kimball, driver of the No. 23 Chevrolet® for Carlin, will carry new colors for the month of May as Novo Nordisk, a world leader in diabetes care and Kimball's longtime partner of 10 years, promotes...

NVO : 48.72 (-0.55%)
Global Non-insulin Diabetes Therapeutics Market Forecasts to 2022 - Key Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi - ResearchAndMarkets.com

The "Global Non-insulin Diabetes Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

NVO : 48.72 (-0.55%)
MRK : 59.14 (+0.12%)
LLY : 82.07 (+0.50%)
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

PTGX : 6.00 (+0.17%)
LGND : 194.99 (+2.01%)
CATB : 1.62 (+1.89%)
NVO : 48.72 (-0.55%)
Stock Review for Drug Makers Investors -- Endo, Ionis Pharma, Novo Nordisk, and United Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ENDP, IONS, NVO, and UTHR which can be accessed for free by signing up to www.wallstequities.com/registration....

ENDP : 6.10 (-1.61%)
NVO : 48.72 (-0.55%)
IONS : 44.64 (+1.85%)
UTHR : 106.27 (-1.33%)
Emisphere Amends License Agreement with Novo Nordisk

Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the development and commercialization...

EMIS : 2.2100 (+7.28%)
NVO : 48.72 (-0.55%)
Global Biopharmaceutical Market 2018-2023 - Key Players are Roche, Amgen, Novo Nordisk, AbbVie and Sanofi

The "Global Biopharmaceutical Market Report & Forecast (2018-2023)" report has been added to ResearchAndMarkets.com's offering.

NVO : 48.72 (-0.55%)
AMGN : 176.30 (+0.94%)
Xultophy® approved in Canada for the treatment of adults with type 2 diabetes

Xultophy® approved in Canada for the treatment of adults with type 2 diabetes

NVO : 48.72 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 49.03
1st Resistance Point 48.88
Last Price 48.72
1st Support Level 48.43
2nd Support Level 48.13

See More

52-Week High 58.37
Fibonacci 61.8% 51.65
Fibonacci 50% 49.57
Last Price 48.72
Fibonacci 38.2% 47.50
52-Week Low 40.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar